AusperBio

The AusperBio team was excited to attend The Science of HBV Cure Meeting 2024 in Singapore on July 26-27. This prestigious event brought together leading experts, researchers, and innovators dedicated to advancing the cure for hepatitis B. It was a valuable opportunity for us to connect with experts, share our developments, and gain insights from others in the field. #AusperBio #HBVCure #Biotech #Innovation #HepatitisB #Singapore2024

🎉🎉🎉We are excited to announce the successful completion of a $37 million Series A financing round! This milestone will support the clinical development of our lead product, AHB-137, and advance our Med-Oligo™ technology platform. Thank you to our investors for their continued support! 🚀🚀🚀 https://lnkd.in/gDjFCbPV #AusperBio #SeriesA #HepatitisB #Biotech #ClinicalTrial #FunctionalCure

We're pleased to share that AusperBio's AHB-137 has achieved Breakthrough Therapy Designation for Chronic Hepatitis B treatment. This milestone marks a significant acceleration in our development efforts, promising new possibilities for HBV patients. Dive into the details: https://lnkd.in/gKvKWMj5 #AusperBio #CHB #BreakthroughTherapy #Biotech #HealthcareInnovation #ClinicalTrials #LiverHealth #HBVTreatment

🔬 Exciting Update from AusperBio 🔬 We are proud to announce significant progress in the clinical development of AHB-137 for chronic hepatitis B (CHB). These developments highlight our commitment to finding innovative solutions and improving patient outcomes. For an in-depth look at our latest developments, read the full press release: https://lnkd.in/gr9cYqUN #Biotech #HepatitisB #ClinicalTrials #AusperBio #HBVCure #HealthcareInnovation

📢 Important Update from AusperBio 📢 We are proud to announce that AusperBio will be presenting the latest clinical data updates for AHB-137 at the EASL Congress 2024! This event is a significant milestone for us as we continue to advance our research and development in the field of liver diseases. 📰 Read the full press release here: https://lnkd.in/ggpFEY36 Our presentation will provide detailed results and key findings from the AHB-137 Phase I clinical trials, demonstrating significant advancements in our research. Join us at the EASL Congress 2024 to learn more about our data and the potential impact on chronic HBV treatment. Thank you to our dedicated team, partners, and supporters for making this possible. We look forward to sharing more exciting updates with you! #AusperBio #EASL2024 #ClinicalResearch #Innovation #Biopharmaceuticals #Hepatitis B

🌍 May is International Hepatitis Awareness Month, and at AusperBio, we're committed to finding a cure for Hepatitis B (HBV), a life-threatening liver infection affecting over 250 million people. According to the WHO's 2024 Global Hepatitis Report, viral hepatitis was the second leading cause of death from communicable diseases in 2022, after COVID-19. This month, let's raise awareness and make a difference: ✅ Learn about hepatitis B and its risks. ✅ Advocate for screenings and vaccinations. ✅ Support those affected by sharing their stories. Together, we can move closer to a world free of HBV. #HepatitisAwarenessMonth #EndHepatitis #HBVCure #HealthcareInnovation #YourCompanyName 🔬 Learn more about our efforts and the latest advancements in HBV research at www.ausperbio.com.

Excited to share the highlights from our recent seminar featuring Dr. Low, Presidential Scholar of Drug Discovery & Ralph Corley Distinguished Professor of Chemistry from Purdue University! Held near the stunning West Lake on April 25, 2024, Dr. Low captivated us with groundbreaking medical discoveries, spanning Fluorescence guided surgery of cancer, Design of targeted drugs to reprogram the immune system, Development of ligand-targeted chemotherapies and radiotherapies for Cancer treatment, Use of hydroxyapatite-targeting peptides to accelerate bone and soft tissue regeneration, Design of targeted therapies for the treatment of viral and other infectious diseases, and much more. His research is reshaping Cancer treatment and beyond. With insights into drug delivery technologies and inspiring words for young scientists, Dr. Low left us with valuable wisdom: 'When you learn something new, always ponder “how can I use that information to do something that matters” – not how can I store the information?' 🌟 A huge thank you to everyone who joined and contributed to our discussions. Let's keep driving innovation in #NextGenDelivery, #MedicalInnovation #Healthcare #InfectiousDiseases #CellTherapy #CancerTherapy and #Biotech together!

AusperBio Announces Major Progress in AHB-137 Clinical Development https://lnkd.in/gWpkAakd